Zimmer Biomet (NYSE:ZBH) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Zimmer Biomet (NYSE:ZBH) posted its earnings results on Thursday. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01, RTT News reports. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. During the same quarter last year, the firm posted $2.20 EPS. Zimmer Biomet updated its FY 2025 guidance to 8.150-8.350 EPS.

Zimmer Biomet Trading Down 5.4 %

ZBH stock traded down $5.79 during mid-day trading on Thursday, reaching $102.46. 2,702,880 shares of the stock traded hands, compared to its average volume of 1,742,429. The business has a 50-day moving average price of $107.75 and a two-hundred day moving average price of $108.20. The stock has a market capitalization of $20.40 billion, a PE ratio of 19.52, a PEG ratio of 1.88 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet has a one year low of $100.67 and a one year high of $133.90.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.94%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Barclays lowered their price objective on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a report on Thursday, December 12th. Oppenheimer decreased their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 15th. Wells Fargo & Company upped their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Finally, Raymond James decreased their price objective on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $124.11.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.